Patent · US Active

Use of low dose IL-2 for treating autoimmune—related or inflammatory disorders

US10765723B2 · kind B2 · utility

4Cited by

3References

10Claims

0Family size

Assignees

INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) · FR
ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS (APHP) · FR
Sorbonne Universite · FR

Inventors

David Klatzmann · Paris, FR
David Saadoun · Neuilly-sur-Seine, FR
Patrice Cacoub · Dozulé, FR
Michèle Rosenzwajg · Paris, FR
Eliane Piaggio · Paris, FR
Gilbert Bensimon · Villejuif, FR
Claude Bernard · Malakoff, FR

Key dates

Filing date	Mar 22, 2019
Grant date	Sep 8, 2020
Priority date	—
Expiry date	Mar 22, 2039

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P37/08
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to novel therapies for treating autoimmune and inflammatory diseases. More specifically, the present invention relates to a use of low dose interleukin-2 for the treatment of type I diabetes and other autoimmune and/or inflammatory diseases.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.